Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial

Cancer Journal

Volumn 7, Issue 5, 2001, Pages 377-387

  Rosen, Lee S ^a,b,k   Gordon, David ^a,c   Kaminski, Mary ^a,d   Howell, Anthony ^a,e   Belch, Andrew ^a,f   Mackey, John ^a,f   Apffelstaedt, J ^a,g   Hussein, Mohamed ^a,h   Coleman, Robert E ^a,i   Reitsma, Dirk J ^a,j   Seaman, John J ^a,j   Chen, Bee Lian ^a,j   Ambros, Yvonne ^a,j  

^a University of California Los Angeles ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^d American Medical Research Institute   (United States)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f CROSS CANCER INSTITUTE   (Canada)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ WESTON PARK HOSPITAL   (United Kingdom)

^j NOVARTIS PHARMA AG   (Switzerland)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Bisphosphonate; Bone metastases; Breast cancer; Myeloma; Supportive care

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CALCIUM; HORMONE; MULTIVITAMIN; PAMIDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INCIDENCE; KIDNEY DISEASE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OSTEOLYSIS; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; BONE TUMOR; BREAST TUMOR; COMPARATIVE STUDY; METASTASIS; MIDDLE AGED; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTICENTER STUDIES; MULTIPLE MYELOMA;

EID: 0035463593     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29-40.
3. Hauschka PV, Mavrakos AE, Iafrati MD et al. Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986;261:12665-12674.
4. Pfeilschifter J, Mundy GR. Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987;84:2024-2028.
5. Yoneda T, Williams P, Dunstan C et al. Growth of metastatic cancer cells in bone is enhanced by bone derived insulin-like growth factors (IGFs). J Bone Miner Res 1995;10[suppl 1]:P269.
6. Guise TA, Yin JJ, Taylor SD et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-1549.
7. Orr FW, Lee J, Duivenvoorden WC et al. Pathophysiologic interactions in skeletal metastasis. Cancer 2000;88:2912-2918.
8. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
9. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-2696.
10. Sato M, Grasser W, Endo N et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
11. Carano A, Teitelbaum SL, Konsek JD et al. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-461.
12. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991;49:407-415.
13. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
14. Rogers MJ, Chilton KM, Coxon FP et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 1996;11:1482-1491.
15. Coxon FP, Helfrich MH, Van't Hof R et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-1476.
16. Aparicio A, Gardner A, Tu Y et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-229.
17. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-2221.
18. Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-1468.
19. Shipman CM, Rogers MJ, Apperley JF et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997;98:665-672.
20. Shipman CM, Croucher PI, Russell RG et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-5297.
21. Tassone P, Forciniti S, Galea E et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-844.
22. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-493.
23. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
24. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
25. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-2044.
26. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854.
27. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082-1090.
28. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
29. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
30. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
31. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138.
32. Cook RJ, Major R Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001;93:534-538.
33. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
34. Conte PF, Latreille J, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol 1996;14:2552-2559.
35. Lipton A, Demers L, Curley E et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998:34:2021-2026.
36. Souberbielle JC, Cormier C, Kindermans C. Bone markers in clinical practice. Cur Opin Rheumatol 1999;11:312-319.
37. Vinholes JJ, Purohit OP, Abbey ME et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997:8:1243-1250.
38. Woitge HW, Pecherstorfer M, Li Y et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999;14:792-801.
39. Demers LM, Costa L, Chinchilli VM et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-1494.
40. Vinholes J, Coleman R, Lacombe D et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 1999:80:221-228.
41. Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999;21:389-406.